Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma by Maura C. Gillis, BA, Vanessa R. Weir, BA, Cecilia Lezcano, MD, Gopa Iyer, MD, Allison Gordon, MD

Get full text